TScan Therapeutics develops engineered T cell therapies, including TCR-T product candidates that are still in clinical development. It last closed at $0.15 on Nov 20, up 2.24% on the day. The next earnings report for TCRX is expected around Wed, Mar 3, 2027. For the quarter ended Sep 2026, TCRX reported EPS of -$0.25 on revenue of $586,000, with revenue down 76.7% from a year ago. Over its last 8 reports the stock moved an average of 4.8% the session after earnings. Over the last 12 months TCRX insiders bought $146K of stock on the open market and sold $0, according to SEC Form 4 filings.
AI Auto Pilots
Is TCRX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold TCRX.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on TCRXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
TCRX · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold
The stock is 20% below its 20 day and 64% below its 50 day average. It is 437% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 31), near oversold. The nearest support is the 52 week low at $0.14, and the nearest resistance the Pivot at $0.15.
Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityHigh, 14.8%/day
Key levels
$1.4752 week high+880.0%
$0.78200 day average+420.0%
$0.51100 day average+240.0%
$0.2450 day average+60.0%
$0.21Swing high (Nov 4)+40.0%
$0.1820 day average+20.0%
$0.15Pivot R1+0.0%
$0.15Pivot+0.0%
$0.15Last close
$0.1452 week low−6.7%
$0.14Pivot S1−6.7%
Indicators
RSI (14)
30.63
Weak, oversold below 30
Neutral
MACD
-0.03
Below its signal line
Bearish
Stochastic
7.8
Near the bottom of its range
Oversold
ADX (14)
52.1
Strong downtrend
Williams %R
-91.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-129.7
Oversold below −100, overbought above 100
Oversold
Rate of change
−22.4%
Change over 10 sessions
Bearish
ATR (14)
$0.02
Typical daily range, 14.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 73.2%/day
Key levels
$1.4752 week high+880.0%
$0.78200 day average+420.0%
$0.51100 day average+240.0%
$0.2450 day average+60.0%
$0.21Swing high (Nov 4)+40.0%
$0.1820 day average+20.0%
$0.15Pivot R1+0.0%
$0.15Pivot+0.0%
$0.15Last close
$0.1452 week low−6.7%
$0.14Pivot S1−6.7%
Indicators
RSI (14)
22.63
Oversold below 30
Oversold
MACD
-0.23
Below its signal line
Bearish
Stochastic
1.1
Near the bottom of its range
Oversold
ADX (14)
29.6
Trending down
Williams %R
-99.2
Oversold below −80, overbought above −20
Oversold
CCI (20)
-83.6
Oversold below −100, overbought above 100
Neutral
Rate of change
−54.5%
Change over 10 sessions
Bearish
ATR (14)
$0.11
Typical daily range, 73.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for TCRX
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how TCRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow TCRX usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for TCRXHow many large options trades hit TCRX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in TCRX in the last 90 days.
From SEC Form 4 filings by TCRX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TCRX is in one of them and how their past TCRX trades turned out.
TScan Therapeutics is a biological products company based in Waltham, Massachusetts, that develops engineered T cell therapies. Its main focus is a set of TCR-T therapy product candidates, which are still in development and are being studied in clinical trials. These candidates are meant for physicians and the patients they treat, and the company must manufacture them and win regulatory approval before they can be sold. The company relies on contract research organizations, clinical sites and outside manufacturers to carry out its work.